- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03476109
Study of Magnitude and Prediction of Response to Omalizumab and Mepolizumab in Adult Severe Asthma. (PREDICTUMAB)
Predictive Factors and Magnitude of Response to Omalizumab and Mepolizumab in Allergic and Eosinophilic Severe Asthma: a Pragmatic Multicenter Trial in Belgium.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Title "PREDICTUMAB: Predictive factors and magnitude of response to omalizumab and mepolizumab in allergic and eosinophilic severe asthma: a multicenter, open, active-controlled, randomized trial in adult patients in Belgium".
Rationale and background New treatments are now available to treat severe refractory asthma, which affects about 3 to 5% of asthma patients. In particular, biological therapies using monoclonal antibodies targeted to immunoglobulin E (IgE) or interleukin (IL)-5 (and in the future other cytokines or growth factors) benefit to certain patients. Identifying those patients who will better benefit from a specific treatment requires the validation of features (clinical traits, biomarkers) that are predictive of the therapeutic outcome. Such predictive strategy is not available to decide whether anti-IgE (omalizumab) or anti-IL-5 (mepolizumab) should be prioritized in patients who are eligible to both therapies. In addition, the comparison of the magnitude of the clinical benefits achieved by these therapies remains unexplored in this population.
Study Design
The study is designed to initially randomly allocate patients from two strata (with or without maintenance oral corticosteroids) to oma- vs mepolizumab. According to the evaluation of response (at 4 or 6 months, respectively), subjects will then be either prolonged (for 12 months, for both therapies) on the same therapy, or switched to the other. For those who were switched, treatment will be prolonged (or not, in dual failers) after 4 or 6 months according to their evaluation of response. Time-points for analysis will be at 4 or 6 months, 10 months (interim analysis) and 18 or 22 months (final, posttreatment analysis).
State-of-the-art
Asthma is one of the most frequent chronic diseases, affecting 5 to 10% of the population worldwide. Omalizumab and mepolizumab represent the approved antibodies that are indicated in allergic and eosinophilic phenotypes of severe asthma respectively. However, if some patients fall into only one phenotypic category based on these criteria, a substantial number of patients are potentially eligible to both therapies. In those patients, no information is available to orientate towards a preferable therapy as the predictive weight of additional phenotypic traits, such as associated nasal polyps or early- versus late onset of disease, remains unknown. In addition, no head-to-head comparison of these therapies is available in this population.
Objectives of the study
Primary objectives To determine clinical features and blood (or sputum) biomarkers able to predict a better response to omalizumab or mepolizumab in severe asthma patients eligible to both therapies.
To determine the magnitude of response, in terms of improvement in symptoms, exacerbation rate and/or lung function, in responders to omalizumab vs mepolizumab.
Secondary objectives To compare the global baseline characteristics (clinical and biological features) of patients responding to omalizumab vs mepolizumab.
Management and reporting of adverse events.
If during the study, an adverse event (AE) (serious or non-serious) is identified as attributed to omalizumab or mepolizumab, this will be documented as appropriate in routine good clinical practice, to the Federal Agency of Medicines and Products of Health (AFMPS) as well as to the Central Ethic Committee.
Confidentiality of data.
The identity and participation of subjects will remain strictly confidential, according to Belgian laws dated 8 Dec 1992 related to the protection of private life and dated 22 Aug 2002 related to patient rights.
Specimens and associated data will be labeled with unique patient identification number.
Data will be anonymized in all files, results and publications related to the study.
The promoter confirms to authorize the regulatory surveillance, examination and controls by competent authorities, by allowing direct access to database/files, and this in full respect of confidentiality.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Charles Pilette, MD PhD
- Phone Number: 2866 003227642866
- Email: charles.pilette@uclouvain.be
Study Contact Backup
- Name: Irina Kaidalina-Mambour, Inf
- Phone Number: 2813 003227642813
- Email: irina.kaidalina-mambour@uclouvain.be
Study Locations
-
-
-
Brussels, Belgium, 1200
- Recruiting
- Cliniques Universitaires St-Luc
-
Contact:
- Irina Kaidalina-Mambour, Inf
- Phone Number: 2813 003227642813
- Email: irina.kaidalina-mambour@uclouvain.be
-
Contact:
- Pilette Charles, MD PhD
- Phone Number: 2866 003227642866
- Email: charles.pilette@uclouvain.be
-
Bruxelles, Belgium, 1000
- Not yet recruiting
- Centre Hospitalier Universitaire Saint Pierre
-
Contact:
- Vincent Ninane, MD
-
Bruxelles, Belgium, 1020
- Not yet recruiting
- Brugmann University Hospital
-
Contact:
- Olivier Michel, MD, PhD
-
Bruxelles, Belgium, 1070
- Not yet recruiting
- Erasme University Hospital
-
Contact:
- Alain Michils, MD
-
Gent, Belgium, 9000
- Not yet recruiting
- University Hospital, Ghent
-
Contact:
- Guy Brusselle, MD, PhD
-
Liège, Belgium, 4000
- Not yet recruiting
- University Hospital of Liege
-
Contact:
- Florence Schleich, MD, PhD
-
Namur, Belgium, 5000
- Not yet recruiting
- CHR Namur
-
Contact:
- Vincent Hers, MD
-
Namur, Belgium, 5530
- Not yet recruiting
- Centre Hospitalier Universitaire Dinant Godinne - UCL Namur
-
Contact:
- Olivier Vandenplas, MD, PhD
-
-
Brussels
-
Brussel, Brussels, Belgium, 1090
- Not yet recruiting
- Universitair Ziekenhuis Brussel
-
Contact:
- Shane Hanon, MD
-
-
Hainaut
-
Charleroi, Hainaut, Belgium, 6000
- Not yet recruiting
- CHU de Charleroi
-
Contact:
- Rudi Peche, MD
-
Charleroi, Hainaut, Belgium, 6000
- Not yet recruiting
- Grand Hôpital de Charleroi
-
Contact:
- Pol-Marie Mingeot, MD
-
-
Vlaams Brabant
-
Leuven, Vlaams Brabant, Belgium, 3000
- Not yet recruiting
- Katholieke Universiteit Leuven
-
Contact:
- Lieven Dupont, MD, PhD
-
-
West-vlaanderen
-
Roeselare, West-vlaanderen, Belgium, 8800
- Not yet recruiting
- AZ Delta Roeselare
-
Contact:
- Ulriche Himpe, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria: • Signed informed consent form (ICF),
- Age >18+ years at time of signing ICF,
- Able to comply with the study protocol, in the investigator's judgment,
- Documented physician-diagnosed asthma ,
- Patients with severe disease and eligible to omalizumab and mepolizumab, and who have not yet received any of these therapies.
Exclusion Criteria:
- History of evidence of drug/substance abuse that would pose a risk to patient safety, interfere with the conduct of study, have an impact on the study results, or affect the patient's ability to participate in the study, in the opinion of the investigator
- Treatment with any investigational therapy within 6 months or 5 drug half-lives prior to enrolment.
- Known sensitivity to any of the active substances or their excipients to be administered during the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Omalizumab
Patients randomized to omalizumab and then prolonged or not (based on their response at 4 months) until the end of the study (22mo). Non responders will be switched to mepolizumab arm. |
The only intervention will be that allocation of patients to omalizumab or mepolizumab (to both of which patients will be eligible) will be randomized, to avoid that the initial decision is biased by confounding factors that are likely, but unproven, to affect the treatment response.
Then, in case of non-response, patients will be switched to the other drug, as routine clinical practice would indicate.
Other Names:
|
Active Comparator: Mepolizumab
Patients randomized to mepolizumab and then prolonged or not (based on their response at 6 months) until the end of the study (22mo). Non responders will be switched to omalizumab arm. |
The only intervention will be that allocation of patients to omalizumab or mepolizumab (to both of which patients will be eligible) will be randomized, to avoid that the initial decision is biased by confounding factors that are likely, but unproven, to affect the treatment response.
Then, in case of non-response, patients will be switched to the other drug, as routine clinical practice would indicate.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy on asthma symptoms
Time Frame: Up to 22 months
|
Asthma Control Test: 5 items of score 1 to 5 about symptoms, with result of 20 or above indicates good control; 15 to 19 indicates no good control and below 15 indicates no control at all, and a change of 3 points considered as clinically significant.
|
Up to 22 months
|
Efficacy on lung function
Time Frame: Up to 22 months
|
Lung function measured as forced expiratory volume in one sec (FEV1), % predicted value (normal value of 80% predicted or above, and change of 100 mL considered as clinically significant).
|
Up to 22 months
|
Efficacy on severe exacerbations
Time Frame: Up to 22 months
|
Number of exacerbation(s) per period of time (corrected per year) requiring systemic corticosteroid treatment for at least 3 days, and/or emergency visit or hospitalization for acute asthma.
|
Up to 22 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Predictive factors of therapeutic response
Time Frame: Baseline features (and according to response at 22 months)
|
The putative predictive factors of therapeutic response to omalizumab or mepolizumab which will be assayed are the following: age at onset, year (> or < 30yrs); presence of nasal polyps, Y/N; blood eosinophils, n/microliter (< or > 300/microl); serum total IgE, units/L; serum periostin, ng/ml.
A proteomic analysis will also be carried out on plasma samples.
|
Baseline features (and according to response at 22 months)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Charles Pilette, Cliniques Universitaires Saint-Luc
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017/19JUI/325
- PNEU-ASTHMA-02 (Other Identifier: CUSL)
- 2017-002473-19 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Severe Asthma
-
Gert-Jan BraunstahlGenzyme, a Sanofi CompanyCompleted
-
AstraZenecaCompleted
-
Bio-Thera SolutionsCompleted
-
KoBioLabsNovotech (Australia) Pty LimitedCompletedModerate to Severe AsthmaAustralia
-
Tufts Medical CenterCompleted
-
University of KarachiEnrolling by invitationAsthma AcutePakistan
-
Universitair Ziekenhuis BrusselUnknownCOPD | Severe AsthmaBelgium
-
German Asthma Net e.V.Sanofi; GlaxoSmithKline; AstraZeneca; Chiesi Farmaceutici S.p.A.Recruiting
-
Assistance Publique - Hôpitaux de ParisRecruiting
-
Scarlata, Simone, M.D.IRCCS San RaffaeleRecruiting
Clinical Trials on Randomisation to mepolizumab
-
AstraZenecaActive, not recruitingEosinophilic Granulomatous VasculitisUnited States, Canada, France, Italy, Israel, United Kingdom, Japan, Germany, Belgium
-
Queen's University, BelfastCompleted
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Dutch Lung FoundationCompletedAsthma in ChildrenNetherlands, Belgium, Switzerland
-
Queen's University, BelfastCompleted
-
GlaxoSmithKlineCompletedAsthmaUnited States, Argentina, Australia, Germany, Poland, Romania, Russian Federation, Ukraine, Canada, Chile, France, Korea, Republic of, United Kingdom
-
Academisch Medisch Centrum - Universiteit van Amsterdam...GlaxoSmithKline; The Netherlands Asthma FoundationUnknownAsthma | Viral InfectionNetherlands
-
Groupe Hospitalier Diaconesses Croix Saint-SimonCompletedArthropathy | HipFrance
-
Fondazione Policlinico Universitario Agostino Gemelli...Not yet recruitingChronic Rhinosinusitis With Nasal PolypsItaly
-
GlaxoSmithKlineRecruitingEosinophilic Granulomatosis With PolyangiitisCanada, France, Italy, Spain, Belgium, Korea, Republic of, United States, Japan, China, Czechia, Hungary, Israel, Portugal, Poland, Netherlands, United Kingdom, Austria, Argentina, Australia, Brazil, Germany, Sweden
-
GlaxoSmithKlineCompletedAsthmaUnited States, Argentina, Australia, Canada, France, Germany, Japan, Russian Federation, Spain, Ukraine, Belgium, Chile, Korea, Republic of, Mexico, Italy, United Kingdom